ReviewImmunology and cell biology
Langerhans cells as targets for immunotherapy against skin cancer.
Review in Immunology and cell biology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 56 citations in OpenAlex.
- Research Progress of Microneedles in Vaccine Delivery.Current medicinal chemistry · 2026Review
- In Situ Cancer Vaccines: Redefining Immune Activation in the Tumor Microenvironment.ACS biomaterials science & engineering · 2025Review
- Assessing the Correlation Between Langerhans Cells Population and Prognosis of Tongue Squamous Cell Carcinoma.Clinical and experimental dental research · 2025Article
- TIME Is Ticking for Cervical Cancer.Biology · 2023Review
- Poly(β-amino ester)s-Based Delivery Systems for Targeted Transdermal Vaccination.Pharmaceutics · 2023Article
- Recent advances in epicutaneous immunotherapy and potential applications in food allergy.Frontiers in allergy · 2023Review
- Skin immunity in wound healing and cancer.Frontiers in immunology · 2023Review
- Antigen targeting to dendritic cells: Still a place in future immunotherapy?European journal of immunology · 2022Review
- Recent Development of Ruminant Vaccine Against Viral Diseases.Frontiers in veterinary science · 2021Review
- A Liposomal Platform for Delivery of a Protein Antigen to Langerin-Expressing Cells.Biochemistry · 2019Article
- Vaccine delivery systems.Human vaccines & immunotherapeutics · 2017Article
- Modulating Both Tumor Cell Death and Innate Immunity Is Essential for Improving Radiation Therapy Effectiveness.Frontiers in immunology · 2017Review
- Functional Specialization of Skin Dendritic Cell Subsets in Regulating T Cell Responses.Frontiers in immunology · 2015Review
- Autologous therapies in dermatology.The Journal of clinical and aesthetic dermatology · 2014Review
- Exploitation of Langerhans cells for in vivo DNA vaccine delivery into the lymph nodes.Gene therapy · 2014Article
- Epicutaneous Immunotherapy for Aeroallergen and Food Allergy.Current treatment options in allergy · 2014Review
- Laser microporation of the skin: prospects for painless application of protective and therapeutic vaccines.Expert opinion on drug delivery · 2013Review
- Understanding dendritic cells and their role in cutaneous carcinoma and cancer immunotherapy.Clinical & developmental immunology · 2013Review
- Harnessing DNA-induced immune responses for improving cancer vaccines.Human vaccines & immunotherapeutics · 2012Review
- Langerhans cells from human cutaneous squamous cell carcinoma induce strong type 1 immunity.The Journal of investigative dermatology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Cancer is the second most common cause of death in the world. Treatment of cancer is very challenging and immunotherapy has been developed as a potential way to fight cancer. The main obstacle with immunotherapy is that cancer cells evolve from healthy body cells in response to an accumulation of genetic mutations. As a consequence, the immune system struggles to detect the abnormal cells as they are mainly recognized as self. This implies that equipping the immune system to eliminate cancer cells is tricky, yet represents a very efficient way to constrain the growth of tumors. We became interested in developing immunotherapeutical strategies against skin cancer in the context of our observations that Langerhans cells (LC) are very potent antigen presenting cells and are able to incorporate protein antigens and present them to CD4(+) and CD8(+) T cells in the skin-draining lymph nodes. As a consequence, we developed an immunization strategy through the skin, termed epicutaneous immunization. Protein antigen applied onto barrier-disrupted skin induces long-lasting cytotoxic T-cell responses, potent enough to control and inhibit tumor growth. In this review, we suggest that immunization strategies through the skin could be a promising new approach for the treatment of skin cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.